Evaluation of Right Ventricular Function to Predict Weaning Success in the Intensive Care Unit

NCT07073976 · tracked via the Priya Life Science Turkey tracker

Sponsor

Kanuni Sultan Suleyman Training and Research Hospital

Phase

Observational

Started

2025-07-31

Last updated

2025-09-09

Condition(s) studied

Weaning Failure of Mechanical Ventilation

Investigational drug(s) / intervention(s)

Transthoracic Echocardiography (TTE)

Transthoracic Echocardiography (TTE): Non-invasive ultrasound imaging of the heart to evaluate right ventricular and right atrial function using parameters such as TAPSE, tricuspid S', RV-FAC, right atrial area, and pulmonary valve acceleration time. TTE will be performed once within 2 hours prior to extubation decision as part of routine care.

Study summary

The goal of this prospective observational study is to evaluate whether right ventricular (RV) function parameters assessed via transthoracic echocardiography (TTE) can predict weaning success in adult intensive care unit (ICU) patients who are mechanically ventilated. The main questions it aims to answer are:

Can the TAPSE (Tricuspid Annular Plane Systolic Excursion) value predict successful extubation?

Do other right heart parameters (tricuspid S', RV-FAC, right atrial area, pulmonary valve acceleration time) provide additional prognostic value for weaning outcomes?

Participants will:

Be adult ICU patients planned for weaning from mechanical ventilation.

Undergo transthoracic echocardiography within 2 hours after meeting clinical weaning criteria.

Have the following echocardiographic parameters measured: TAPSE, tricuspid S', RV-FAC, right atrial area, and pulmonary valve acceleration time.

Be monitored for 24 hours after extubation to assess weaning success (defined as no need for reintubation, non-invasive ventilation, or high-flow oxygen support).

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Receiving invasive mechanical ventilation in the ICU * Planned extubation (weaning) according to standard clinical criteria * Hemodynamically stable at the time of transthoracic echocardiography (TTE) * Ability to undergo echocardiographic assessment within 2 hours prior to extubation * Informed consent obtained from patient or legal representative Exclusion Criteria: * Known severe tricuspid valve disease or congenital heart disease * Moderate to severe pericardial effusion or cardiac tamponade * Inadequate acoustic window for transthoracic echocardiography * Patients requiring urgent or unplanned extubation * Use of extracorporeal life support (e.g., ECMO) at the time of assessment * Known pulmonary embolism or acute cor pulmonale * Pregnancy

Primary outcome measure(s)

Discriminative Ability of TAPSE for Predicting Weaning Success — Within 24 hours after extubation
Assessment of the predictive accuracy of TAPSE (Tricuspid Annular Plane Systolic Excursion) in identifying weaning success, defined as no requirement for reintubation, non-invasive ventilation, or high-flow oxygen within 24 hours post-extubation.

Trial sites (1)

Facility	City	Region	Status
Health Science University İstanbul Kanuni Sultan Süleyman Education and Training Hospital	Istanbul	Istanbul	Recruiting

More Kanuni Sultan Suleyman Training and Research Hospital trials in Turkey

Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women? Recruiting

Caudal Block vs Retrolaminar Block on Analgesic Consumption in Undescended Testis Surgeries Recruiting

Post-hysterectomy Vaginal Cuff Prolapse Repair Recruiting

ESWT vs Conventional Physical Therapy in Greater Trochanteric Pain Syndrome Recruiting

Evaluation of AI Models in Determining the Optimal PEEP Recruiting

Other trials for the same condition

Combined Predictive Value of RSBI and CALLY Index in Predicting Weaning Success in ICU Patients Recruiting

Evaluation of Left Ventricular Function to Predict Weaning Success in the Intensive Care Unit Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07073976 on ClinicalTrials.gov ↗ ← All trials in Turkey